Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

The Ocular Hypertension pipeline market research report provides an overview of the Ocular Hypertension pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Hypertension and features dormant and discontinued projects.

Ocular Hypertension Pipeline Drugs Market by Key Targets

Some of the targets of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A. Prostaglandin F2 Alpha Receptor has the highest number of pipeline products.

Ocular Hypertension Pipeline Drugs Market, by Targets

Ocular Hypertension Pipeline Drugs Market, by Targets

For more target insights, download a free report sample

Key Mechanisms of Action in the Ocular Hypertension Pipeline Drugs Market

Some of the mechanisms of action of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist.

Ocular Hypertension Pipeline Drugs Market, by Mechanisms of Action

Ocular Hypertension Pipeline Drugs Market, by Mechanisms of Action

For more mechanisms of action insights, download a free report sample

Key Routes of Administration in the Ocular Hypertension Pipeline Drugs Market

The routes of administration in the Ocular Hypertension pipeline drugs market are ophthalmic, intraocular, intravitreal, intravenous, oral, parenteral, buccal, conjunctival, intraarticular, and nasal.

Ocular Hypertension Pipeline Drugs Market, by Routes of Administration

Ocular Hypertension Pipeline Drugs Market, by Routes of Administration

For more routes of administration insights, download a free report sample

Key Molecule Types in the Ocular Hypertension Pipeline Drugs Market

The molecule types in the Ocular Hypertension pipeline drugs market are small molecule, gene therapy, antisense RNAi oligonucleotide, cell therapy, and protein. Small molecule has the highest number of pipeline products.

Ocular Hypertension Pipeline Drugs Market, by Molecule Types

Ocular Hypertension Pipeline Drugs Market, by Molecule Types

For more molecule type insights, download a free report sample

Key Ocular Hypertension Pipeline Drugs Market Companies

Some of the key companies in the Ocular Hypertension pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa.

Ocular Hypertension Pipeline Drugs Market, by Key Companies

Ocular Hypertension Pipeline Drugs Market, by Key Companies

To know more about key companies, download a free report sample

Market Report Overview

Key Targets Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A
Key Mechanisms of Action Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist
Key Routes of Administration Ophthalmic, Intraocular, Intravitreal, Intravenous, Oral, Parenteral, Buccal, Conjunctival, Intraarticular, and Nasal
Key Molecule Types Small Molecule, Gene Therapy, Antisense Rnai Oligonucleotide, Cell Therapy, and Protein
Key Companies NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Ocular Hypertension (Ophthalmology).
  • Reviews of pipeline therapeutics for Ocular Hypertension (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which include product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities.
  • Reviews of key companies involved in Ocular Hypertension (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • Evaluation of Ocular Hypertension (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news and deals related to pipeline therapeutics for Ocular Hypertension (Ophthalmology).

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies
  • Recognize emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
  • Find and recognize significant and varied types of therapeutics under development for Ocular Hypertension (Ophthalmology)
  • Classify potential new clients or partners in the target demographic
  • Develop tactical initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics
  • Formulate corrective measures for pipeline projects by understanding Ocular Hypertension (Ophthalmology) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline

FAQs

  • Some of the targets of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor, Beta 1 Adrenergic Receptor, Beta 2 Adrenergic Receptor, Rho Kinase, Alpha 2 Adrenergic Receptor, Carbonic Anhydrase 2, Phosphodiesterase 5, Prostaglandin E2 Receptor EP2 Subtype, Soluble Guanylate Cyclase, and 5-Hydroxytryptamine Receptor 1A.

  • Some of the mechanisms of action of the Ocular Hypertension pipeline drugs market are Prostaglandin F2 Alpha Receptor Agonist, Beta 1 Adrenergic Receptor Antagonist, Beta 2 Adrenergic Receptor Antagonist, Rho Kinase Inhibitor, Alpha 2 Adrenergic Receptor Agonist, Carbonic Anhydrase 2 Inhibitor, Phosphodiesterase 5 Inhibitor, Prostaglandin E2 Receptor EP2 Subtype Agonist, Soluble Guanylate Cyclase Activator, and 5-Hydroxytryptamine Receptor 1A Agonist.

  • The routes of administration in the Ocular Hypertension pipeline drugs market are ophthalmic, intraocular, intravitreal, intravenous, oral, parenteral, buccal, conjunctival, intraarticular, and nasal.

  • The molecule types in the Ocular Hypertension pipeline drugs market are small molecule, gene therapy, antisense RNAi oligonucleotide, cell therapy, and protein.

  • Some of the key companies in the Ocular Hypertension pipeline drugs market are NicOx SA, Santen Pharmaceutical Co Ltd, Ocular Therapeutix Inc, Betaliq Inc, Kowa Co Ltd, Laboratoires Thea SA, Aadi Bioscience Inc, AbbVie Inc, Aerie Pharmaceuticals Inc, and Angelini Spa.

What our clients have to say

More Reports

View More Reports